Elizabeth K. Bancroft, Rosalind A. Eeles

Slides:

Advertisements

Similar presentations

Volume 62, Issue 4, Pages (October 2012)

Advertisements

Early Detection of Prostate Cancer in 2007

The PSA Era is not Over for Prostate Cancer

Volume 54, Issue 2, Pages (August 2008)

Volume 69, Issue 3, Pages (March 2016)

Volume 59, Issue 2, Pages (February 2011)

Volume 68, Issue 2, Pages (August 2015)

Volume 57, Issue 1, Pages (January 2010)

Volume 52, Issue 1, Pages (July 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Testosterone Therapy in Men With Prostate Cancer

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 53, Issue 4, Pages (April 2008)

Volume 71, Issue 1, Pages (January 2017)

Volume 61, Issue 5, Pages (May 2012)

Volume 73, Issue 6, Pages (June 2018)

Volume 64, Issue 4, Pages (October 2013)

Prostate Cancer Epidemic in Sight?

Volume 65, Issue 6, Pages (June 2014)

Volume 61, Issue 3, Pages (March 2012)

Volume 63, Issue 4, Pages (April 2013)

Volume 63, Issue 4, Pages e53-e56 (April 2013)

Volume 52, Issue 1, Pages (July 2007)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 54, Issue 4, Pages (October 2008)

Volume 63, Issue 6, Pages (June 2013)

Volume 69, Issue 3, Pages (March 2016)

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 54, Issue 5, Pages (November 2008)

Volume 68, Issue 3, Pages (September 2015)

P.M.J. Moonen, L.A.L.M. Kiemeney, J.A. Witjes European Urology

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Shaheen Alanee, Kasmintan Schrader, Kenneth Offit European Urology

Laurent Boccon-Gibod European Urology Supplements

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Volume 70, Issue 1, Pages e27-e28 (July 2016)

Volume 74, Issue 3, Pages (September 2018)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Leonard S. Marks, Jiaoti Huang European Urology

Volume 53, Issue 4, Pages (April 2008)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 71, Issue 1, Pages (January 2017)

Volume 65, Issue 6, Pages (June 2014)

Tillmann Loch, Pat Fox Fulgham European Urology

Volume 74, Issue 2, Pages (August 2018)

Volume 68, Issue 4, Pages (October 2015)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

The Role of Genetic Markers in the Management of Prostate Cancer

Volume 50, Issue 5, Pages (November 2006)

Anna Grenabo Bergdahl, Erik Holmberg, Sue Moss, Jonas Hugosson

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Testicular Cancer Variations in Time and Space in Europe

Volume 53, Issue 1, Pages (January 2008)

Volume 59, Issue 4, Pages (April 2011)

European Urology is “Your” Journal

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Volume 52, Issue 6, Pages (December 2007)

Homeobox B13 G84E Mutation and Prostate Cancer Risk

Volume 68, Issue 2, Pages (August 2015)

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Bertrand Tombal, Richard Berges

Volume 54, Issue 3, Pages (September 2008)

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Elizabeth K. Bancroft, Rosalind A. Eeles Corrigendum to “Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study” [Eur Urol 2014;66:489–99] Elizabeth K. Bancroft, Rosalind A. Eeles European Urology Volume 67, Issue 6, (June 2015) DOI: 10.1016/j.eururo.2014.12.001 Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 2 Consort diagram for the first round of screening. BRCA1=breast cancer 1, early onset; BRCA2=breast cancer 2, early onset; PSA=prostate-specific antigen; PPV=positive predictive value. * Controls were men who had a negative predictive genetic test for the BRCA mutation in their family. European Urology 2015 67, DOI: (10.1016/j.eururo.2014.12.001) Copyright © 2014 European Association of Urology Terms and Conditions